


Why Every Tumor Deserves Immediate Injection — A Clinical and Philosophical Perspective on Intratumoral ClO₂ Therapy

Xuewu Liu Jun 30, 2025



Introduction

Cancer is often likened to a wound that does not heal. But unlike a benign wound, tumors have physical mass, invasive tendencies, and systemic implications. They grow, invade, mutate, and kill — silently and persistently. The very presence of a tumor, no matter how small or seemingly inert, is a time bomb ticking toward further degeneration, metastasis, or fatality.

In this article, I argue that with the arrival of a revolutionary therapy — **intratumoral chlorine dioxide (ClO₂) injection**— we must abandon the outdated paradigm that emphasizes delay, caution, or systemic over-treatment. Based on both scientific mechanism and treatment logic, **every visible tumor should be injected as early as possible**, even those located near sensitive structures like the spine or brain. The rationale is simple: **retaining a tumor is almost always riskier than injecting it with a controlled, localized oxidative agent that causes no systemic toxicity.**

This is not merely a technical or clinical recommendation — it is a shift in thinking that requires re-evaluating how we balance perceived risk and actual harm. In fact, this entire framework is underpinned by a philosophical principle I developed over years of battling complex medical problems:

When dealing with complex systems, humans must operate only at levels where the outcomes can be accurately predicted.

In this article, I will lay out:

- The biochemical mechanism of ClO₂ injection
- The misunderstood risk calculus in tumor management
- The philosophical and strategic reasons to prioritize early injection
- The dangers of surgical and systemic delay
- A direct appeal to clinicians to adopt a new standard

Let us begin with the basic mechanism.

Mechanism: Why ClO₂ Works Differently

Chlorine dioxide (ClO₂) is a **potent oxidizer** that acts upon tumor tissues **immediately upon contact**. Its oxidative potential allows it to selectively damage cancerous tissue, leading to **coagulative necrosis**, tumor dehydration, vascular collapse, and inflammation reduction — all localized within the tumor mass.

Its most remarkable feature is that **it reacts completely within the tumor micro-environment**, transforming into benign byproducts — mainly chloride ions (Cl⁻) and water — once its oxidative work is done.

Importantly, its effect **attenuates exponentially** as it diffuses outward. By the time it reaches healthy tissue at the tumor margins, its oxidative strength has dropped significantly. Therefore, **ClO₂ respects anatomical boundaries naturally** through its own chemical limitations, making it safer than most ablative therapies.

Even in anatomically delicate areas such as near the spine, brain, or large vessels, **a slow, controlled, and low-volume injection can be safely executed**, especially under ultrasound or CT guidance.

Conventional Thinking: The Root of Delay

In traditional oncology, clinicians often fear intervening in sensitive areas. The spine, the brain, retroperitoneal spaces — these are zones many surgeons or interventionalists avoid unless absolutely necessary. Instead, they rely on systemic treatments — chemotherapy, immune checkpoint inhibitors, hormonal suppression — or delay until symptoms become severe.

But this leads to two problems:

1. **Tumors grow.** By the time intervention occurs, the tumor is often larger, more fibrotic, more infiltrative, and harder to treat.

2. **Complexity increases.** Delay creates new problems — edema, pain, nerve compression, hemorrhage, and higher technical difficulty for intervention.

This is where my core philosophical principle comes in:

In solving complex problems, we must operate only at layers where the outcome can be **predicted with high confidence**. Waiting until tumors become unpredictable defeats that principle.

In medicine, this means: **early physical intervention with predictable, localized effects should always be prioritized over complex, systemic maneuvers whose outcomes are delayed, diffuse, or uncertain.**

The Mistake of Over-Caution: A Surgical Fallacy

In clinical practice, many doctors approach ClO_2 therapy with **surgical thinking**. They assume that like a scalpel, ClO_2 “cuts” with equal damage to all tissues it touches. But this is false.

Surgeons are trained to think that their tools are neutral in effect — a blade cuts tumor and normal tissue alike. But ClO_2 is not a scalpel. It is a **selective oxidant**. It has **rapid reactivity, limited penetration, and built-in dose decay**.

Here's what traditional thinkers miss:

- **Surgical excision is binary** — cut or not cut.
- **ClO_2 injection is graded** — 2 mL or 8 mL, high concentration or low, deep or shallow.

Even more importantly, when injected into a tumor, **ClO_2 reacts primarily within the high oxidative load of cancerous tissue**. As it spreads outward, it loses activity. **By the time it contacts normal cells, its strength is significantly reduced.**

This unique chemical profile makes ClO_2 ideal for **gradual tumor dissolution from the inside out**, especially in locations where surgery is risky.

To continue using surgical caution as a model for ClO₂ injection is to misunderstand its nature — and to delay potentially life-saving treatment.

The Irreversibility of Delay

Every day a tumor remains untreated, it changes:

- Its size increases.
- Its blood vessels proliferate.
- Its immune environment becomes more evasive.
- Its invasiveness and fibrosis increase.

And most critically: **every delay increases the technical difficulty of injecting it later.**

Imagine trying to inject a 1.5 cm tumor vs. a 4.5 cm one wrapped around nerves. What was once a 10-minute procedure becomes a high-stakes decision.

The **cost of delay is nonlinear** — it accumulates geometrically. That's why early injection is not just better — it's often **the only time you can inject safely and effectively.**